109 related articles for article (PubMed ID: 16624831)
1. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression.
Neilan TG; Jassal DS; Scully MF; Chen G; Deflandre C; McAllister H; Kay E; Austin SC; Halpern EF; Harmey JH; Fitzgerald DJ
Eur Heart J; 2006 May; 27(10):1251-6. PubMed ID: 16624831
[TBL] [Abstract][Full Text] [Related]
2. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumor suppression.
Kuramochi Y; Takagi H; Morita T
Eur Heart J; 2006 Nov; 27(21):2610-1; author reply 2611. PubMed ID: 17018546
[No Abstract] [Full Text] [Related]
3. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
[TBL] [Abstract][Full Text] [Related]
4. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
5. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
[TBL] [Abstract][Full Text] [Related]
6. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy.
Li L; Takemura G; Li Y; Miyata S; Esaki M; Okada H; Kanamori H; Khai NC; Maruyama R; Ogino A; Minatoguchi S; Fujiwara T; Fujiwara H
Circulation; 2006 Jan; 113(4):535-43. PubMed ID: 16449733
[TBL] [Abstract][Full Text] [Related]
7. The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis.
Frias MA; Somers S; Gerber-Wicht C; Opie LH; Lecour S; Lang U
Cardiovasc Res; 2008 Oct; 80(1):69-77. PubMed ID: 18567640
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity.
Khan M; Shobha JC; Mohan IK; Naidu MU; Sundaram C; Singh S; Kuppusamy P; Kutala VK
Phytother Res; 2005 Dec; 19(12):1030-7. PubMed ID: 16372368
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy.
Hamed S; Barshack I; Luboshits G; Wexler D; Deutsch V; Keren G; George J
Eur Heart J; 2006 Aug; 27(15):1876-83. PubMed ID: 16731534
[TBL] [Abstract][Full Text] [Related]
11. Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy.
Wang J; Zhang J; Sun J; Han J; Xi Y; Wu G; Duan KX; Zhang M; Zhou S; Liu Q
Med Hypotheses; 2011 May; 76(5):695-6. PubMed ID: 21345596
[TBL] [Abstract][Full Text] [Related]
12. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice.
Hou G; Dick R; Abrams GD; Brewer GJ
J Lab Clin Med; 2005 Nov; 146(5):299-303. PubMed ID: 16242529
[TBL] [Abstract][Full Text] [Related]
13. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
14. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction.
Hydock DS; Lien CY; Schneider CM; Hayward R
Med Sci Sports Exerc; 2008 May; 40(5):808-17. PubMed ID: 18408619
[TBL] [Abstract][Full Text] [Related]
15. Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis.
Cuneo KC; Fu A; Osusky KL; Geng L
Anticancer Drugs; 2007 Mar; 18(3):349-55. PubMed ID: 17264769
[TBL] [Abstract][Full Text] [Related]
16. Acute exercise protects against doxorubicin cardiotoxicity.
Wonders KY; Hydock DS; Schneider CM; Hayward R
Integr Cancer Ther; 2008 Sep; 7(3):147-54. PubMed ID: 18815146
[TBL] [Abstract][Full Text] [Related]
17. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets.
Sardão VA; Oliveira PJ; Holy J; Oliveira CR; Wallace KB
Cell Biol Toxicol; 2009 Jun; 25(3):227-43. PubMed ID: 18386138
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice.
Riad A; Bien S; Westermann D; Becher PM; Loya K; Landmesser U; Kroemer HK; Schultheiss HP; Tschöpe C
Cancer Res; 2009 Jan; 69(2):695-9. PubMed ID: 19147586
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.
Westermann D; Lettau O; Sobirey M; Riad A; Bader M; Schultheiss HP; Tschöpe C
Biol Chem; 2008 Jun; 389(6):713-8. PubMed ID: 18627295
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: the magnetic bio-nanoparticles as drug carriers.
Sun JB; Duan JH; Dai SL; Ren J; Zhang YD; Tian JS; Li Y
Cancer Lett; 2007 Dec; 258(1):109-17. PubMed ID: 17920762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
